Abstract
The aim of this study was to evaluate the effects of a gonadotropin-releasing hormone analogue (GnRHa), administered through injections or with sustained-release implants, on spermiation and sperm quality in thicklip grey mullet, Chelon labrosus. Male broodstock transferred from extensive lagoons were randomly allocated to three treatment groups: (a) weekly saline injections (Saline-INJ), (b) weekly GnRHa injections (10 μg kg−1 bw; GnRHa-INJ), and (c) a single GnRHa EVAc implant (50 μg kg−1 bw; GnRHa-IMP). Males were maintained with females under the same treatment protocols and allowed to spawn. Sperm condition, density, motility, duration of motility, and androgen levels were evaluated weekly at five sampling points (Days 0, 7, 14, 21, and 28). All males exhibited complete spermiation during the first two weeks (Days 0 and 7), followed by a gradual decline throughout the rest of the study (Days 14 and 21). This pattern of decline was not as evident in the groups treated with GnRHa, especially in the GnRHa-INJ group. Sperm density, motility, and motility duration varied strongly over time; however, no significant differences were observed among treatments. GnRHa treatment prolonged the spermiation period and delayed its seasonal decline without significantly altering sperm quality. These results may enable more frequent sperm collection and greater sperm availability, as inferred from the spermiation condition (SCI) and qualitative observations.